Spyre Therapeutics (SYRE) closed at $104.48 on November 10, 2026, down 4.1% from the previous close, on volume of 974,155 shares (30-day average 1,286,210).
Data as of November 10, 2026.
Spyre Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 10-Nov 8:00 AM ET)
Spyre Therapeutics Announces Grants of Inducement Awards
Globe Newswire (Fri, 6-Nov 4:05 PM ET)
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 3-Nov 4:01 PM ET)
Globe Newswire (Sun, 18-Oct 9:30 AM ET)
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Globe Newswire (Mon, 5-Oct 8:13 PM ET)
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Globe Newswire (Mon, 5-Oct 4:01 PM ET)
Globe Newswire (Tue, 8-Sep 8:00 AM ET)
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Globe Newswire (Tue, 25-Aug 4:01 PM ET)
Market Chameleon (Wed, 15-Apr 5:18 AM ET)
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.
As of November 11, 2026, SYRE stock price climbed to $105.80 with 359,102 million shares trading.
SYRE has a beta of 1.68, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.12 to the broad based SPY ETF.
SYRE has a market cap of $9.89 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, IWM, XBI, VB, VBR.
SYRE has outperformed the market in the last year with a price return of +377.0% while the SPY ETF gained +12.8%. SYRE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +0.4% and +6.8%, respectively, while the SPY returned -1.3% and -1.1%, respectively.
SYRE support price is $100.53 and resistance is $108.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.
